Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.50 |
| ▸ | TSHR | P16473 | 9/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396061 | 0.90 | DHFR (0.57) | DHFRHIF1ALMNAMAPTMEN1 | |
| SCHEMBL23619600 | 0.83 | CYP1A2 (0.50) | DHFRCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL22307619 | 0.83 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL3391705 | 0.81 | APP (0.61) | CYP2D6ALDH1A1NPC1 | |
| SCHEMBL31457009 | 0.80 | KDM4C (0.53) | DHFRCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL27376118 | 0.80 | KDM4C (0.53) | DHFRCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL22301803 | 0.78 | DHFR (0.47) | DHFRCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL3397304 | 0.78 | DHFR (0.49) | DHFRTSHRALDH1A1HIF1AMAPT | |
| SCHEMBL17105218 | 0.78 | CYP1A2 (0.55) | DHFRCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL15277464 | 0.78 | APP (0.63) | DHFRALDH1A1TDP1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| CN-103261202-A | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LTD | 2013-08-21 | — | — | CN | disclosed |
| EP-2619211-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Private Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038980-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | DHFR 852/4885CYP1A2 1237/4885CYP3A4 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.